Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Not Yet Opened 10-22 16:00:00 EDT

7.45

-4.81

-39.23%

盘后7.47

+0.02+0.27%

19:58 EDT

High9.35	Low6.85	Vol26.19M
Open8.99	D1 Closing12.26	Amplitude20.39%
Mkt Cap399.54M	Tradable Cap299.11M	Total Shares53.63M
T/O200.30M	T/O Rate65.23%	Tradable Shares40.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":7.45,"timestamp":1792699200000,"preClose":12.26,"halted":0,"volume":26189866,"hourTrading":{"tag":"盘后","latestPrice":7.47,"preClose":7.45,"latestTime":"19:58 EDT","volume":1209119,"amount":9010654.6792,"timestamp":1792713524283,"change":0.02,"changeRate":0.002685,"amplitude":0.080537},"delay":0,"changeRate":-0.3923327895595432,"floatShares":40149500,"shares":53630000,"eps":-4.41,"marketStatus":"Not Yet Opened","change":-4.81,"latestTime":"10-22 16:00:00 EDT","open":8.99,"high":9.35,"low":6.85,"amount":200303368.90125,"amplitude":0.203915,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.41,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792742400000},"marketStatusCode":0,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":12.26,"preHourTrading":{"tag":"盘前","latestPrice":9,"preClose":12.26,"latestTime":"09:29 EDT","volume":64479,"amount":607448.147772,"timestamp":1792675799942,"change":-3.26,"changeRate":-0.265905,"amplitude":0.4323},"postHourTrading":{"tag":"盘后","latestPrice":7.47,"preClose":7.45,"latestTime":"19:58 EDT","volume":1209119,"amount":9010654.6792,"timestamp":1792713524283,"change":0.02,"changeRate":0.002685,"amplitude":0.080537},"volumeRatio":18.89853,"impliedVol":1.7971,"impliedVolPercentile":0.8486},"requestUrl":"/m/hq/s/AVTX","defaultTab":"news","newsList":[{"id":"2677998161","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2677998161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677998161?lang=en_us&edition=fundamental","pubTime":"2026-10-23 01:51","pubTimestamp":1792691462,"startTime":"0","endTime":"0","summary":"Lam Research  shares sank 10% after the tech giant flagged supply-chain constraints and guided to lower China sales, taking the shine off its fiscal Q1 earnings and revenue beats reported overnight.Intraday trading volume climbed to over 12.7 million from a daily average of roughly 9.33 million.NVE  shares slumped 33% amid heavy trading after the company reported lower fiscal Q2 net income and revenue.Intraday trading volume rose to over 307,000 from a daily average of about 146,000.Wedbush Securities adjusted its price target for Avalo Therapeutics  to $22 from $34, while maintaining its outperform rating.Shares plunged 35% as intraday trading volume surged to over 17.3 million from a daily average of about 972,000.Price: 231.81, Change: -29.00, Percent Change: -11.12","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2357305700.SGD","LU0868494708.USD","NVEC","RDVY","LU2473716301.USD","LU0256863902.USD","LRCC","LU1670628061.USD","BOBP","RULE","LRCX","TEK","BAI","LU1244550494.USD","LU0274383776.USD","AVTX","EPAI","KNOW","LU1069347547.HKD","IE00B1XK9C88.USD","IE00B775H168.HKD","LU0210536198.USD","LU0708995401.HKD","TINY","LU0096362180.USD","QQQG","RDVI","NWKD","LU0061474960.USD","IE00BWXC8680.SGD","ABFL","CLSE","LU2023250504.SGD","TDV","LU0672654240.SGD","PSI","LU0476273544.USD","LU0256863811.USD","IE00BFSS7M15.SGD","LU1066051811.HKD","LRCU","LU0157215616.USD","LU2543165471.USD","IE00BJJMRX11.SGD","LU1144417596.USD","IE00B4JS1V06.HKD","LU0187121727.USD","IE00BJJMRY28.SGD","COWG","IETC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677960823","title":"Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2677960823","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677960823?lang=en_us&edition=fundamental","pubTime":"2026-10-23 00:45","pubTimestamp":1792687500,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics'  abdakibart remains promising for hidradenitis suppurativa, with phase 2 results comparing favorably with AbbVie's  phase 3 lutikizumab data, which Wedbush Securities said supports abdakibart's potential in a Thursday note.The analysts said AbbVie's phase 3 study met its primary endpoint at week 16, as well as several secondary endpoints. However, the absolute response rate was modest compared with the broader competitive landscape and Avalo Therapeutics' phase 2 data.The analysts said they also believe abdakibart has commercial advantages, including less frequent maintenance dosing every four weeks and consistent activity in both biologic-naive and biologic-experienced patients across both dose groups.The company expects to begin phase 3 trials in the first half of 2027, pending the US Food and Drug Administration feedback on study design, the analysts added.Wedbush cut its price target on Avalo to $22 from $34 and reiterated its outperform rating, saying abdakibar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IYH","LU0965509283.SGD","XLV","LU2129689605.HKD","LU0289739699.SGD","LU0158827948.USD","LU0965509010.AUD","LU0069063385.USD","AVTX","LU2237443465.HKD","AGNG","PJP","LU0395794307.EUR","LU1093756325.SGD","RXL","IXJ","BK4581","FTXH","LENZ","ABBV","LU0058720904.USD","VHT","LU0965509101.SGD","LU2089984988.USD","LU2087621335.USD","LU1093756168.USD","LU2347655073.USD","LU1989772923.USD","IE0000B7K699.USD","IE0009355771.USD","LU1236620834.HKD","TRUH","JDOC","FHLC","LU1236620750.USD","LU2133065610.SGD","MEDX","LU1037948897.HKD","LU0234572021.USD","PPH","IE000BZT7R73.USD","IE00B4R5TH58.HKD","LU0820561818.USD","GLAM","LU2129689431.USD","LU0456855351.SGD","BK4533","LU1720051017.SGD","LU2129689514.USD","LU2023251221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677962628","title":"Avalo Plunges After Rival AbbVie's Skin Drug Trial Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2677962628","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677962628?lang=en_us&edition=fundamental","pubTime":"2026-10-22 23:36","pubTimestamp":1792683385,"startTime":"0","endTime":"0","summary":"BUZZ-Avalo plunges after rival AbbVie's skin drug trial disappoints** Shares of drug developer Avalo TherapeuticsAVTX.Ofall 39% to over one-year low of $7.43** Rival AbbVieABBV.Nreports its experiment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nL4N4681PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IXJ","LU0949170772.SGD","LU2023251221.USD","LU0198837287.USD","IE000SO60NU8.SGD","LU0965509283.SGD","LU1670627923.USD","IE00BBT3K403.USD","LU0211328371.USD","SG9999015945.SGD","LU0965508806.USD","XLV","TRUH","FTXH","FHLC","AGNG","MEDX","GLAM","SG9999015952.SGD","PPH","RXL","PJP","VHT","LU2087621335.USD","LU0058720904.USD","LU2237443622.USD","LU2089283258.USD","JDOC","LU1720051108.HKD","LU1003077747.HKD","ABBV","SG9999011175.SGD","IE00BLSP4452.SGD","LU0912757837.SGD","LU0472753341.HKD","LU0211327993.USD","LU0310800379.SGD","IYH","LU1023059063.AUD","LU2468319806.SGD","LU0395794307.EUR","LU1548497426.USD","IE00BSNM7G36.USD","LU1162221912.USD","LU1551013425.SGD","LU1929549753.HKD","LU0708994859.HKD","IE0000B7K699.USD","AVTX","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677962500","title":"Avalo Therapeutics Shares Down 37% After Rival Abbvie Reports Skin Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2677962500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677962500?lang=en_us&edition=fundamental","pubTime":"2026-10-22 23:33","pubTimestamp":1792683188,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nFWN4681R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0170899867.USD","LU0211327993.USD","IXJ","IE00B19Z3581.USD","JDOC","LU0861579265.USD","LU1934455277.USD","FHLC","IE00B42XCP33.USD","LU1003077747.HKD","LU1989772840.SGD","LU0689472784.USD","AVTX","LU2357627491.SGD","SG9999001440.SGD","LU2237443622.USD","TRUH","PPH","IE00BBT3K403.USD","MEDX","LU2237443382.USD","LU0823416689.USD","IE0004445239.USD","LU2347655073.USD","LU0661504455.SGD","LU2133065610.SGD","LU1720051017.SGD","LU0256863811.USD","LU0965509101.SGD","LU0057025933.USD","FTXH","ABBV","IE0009355771.USD","IE000BZT7R73.USD","LU1244550494.USD","LU2129689605.HKD","SG9999011175.SGD","IYH","BK4566","BK4585","XLV","LU0965508806.USD","LU1496350171.SGD","VHT","IE00BJJMRZ35.SGD","RXL","GLAM","LU1718418525.SGD","AGNG","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677281964","title":"Avalo Therapeutics Down Nearly 40%, on Pace for Largest Percent Decrease Since June 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2677281964","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677281964?lang=en_us&edition=fundamental","pubTime":"2026-10-22 23:05","pubTimestamp":1792681500,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc.  is currently at $7.36, down $4.90 or 39.97%--Would be lowest close since July 30, 2025, when it closed at $6.66--On pace for largest percent decrease since June 26, 2023, when it fell 88.69%--Currently down two consecutive days; down 40.45% over this period--Worst two day stretch since the two days ending Sept. 18, 2023, when it fell 42.6%--Down 51.99% month-to-date--Down 59.47% year-to-date; on pace for worst year since 2023, when it fell 99.25%--Down 99.96% from its all-time closing high of $20793.61 on Feb. 27, 2019--Down 58.93% from 52 weeks ago , when it closed at $17.92--Down 67.82% from its 52-week closing high of $22.87 on May 7, 2026--Would be a new 52-week closing low--Traded as low as $6.85; lowest intraday level since July 31, 2025, when it hit $6.57--Down 44.13% at today's intraday low; largest intraday percent decrease since June 26, 2023, when it fell as much as 88.69%All data as of 11:02:46 AM ETSource: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677985964","title":"Avalo Therapeutics, Inc. : Wedbush Cuts Target Price to $22 from $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2677985964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677985964?lang=en_us&edition=fundamental","pubTime":"2026-10-22 22:57","pubTimestamp":1792681059,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nFWN4682F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677969862","title":"Avalo Therapeutics trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2677969862","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677969862?lang=en_us&edition=fundamental","pubTime":"2026-10-22 21:41","pubTimestamp":1792676505,"startTime":"0","endTime":"0","summary":"09:36 EDT Avalo Therapeutics (AVTX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-trading-resumes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-trading-resumes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","AVTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671242930","title":"Avalo Therapeutics Grants New-Employee Stock Options for 101,600 Shares at $15.47 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2671242930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671242930?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:01","pubTimestamp":1790712080,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics grants new-employee stock options for 101,600 shares at $15.47 eachAvalo Therapeutics granted inducement stock options covering 101,600 shares to three newly hired employees.Options","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDLb3KgNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4139","IE00BN0W2V16.EUR","SG9999014021.USD","AVTX","BK4112","IE00BKPKM429.USD","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4585","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","IE00BQXX3C00.GBP","BCDF","IE00BN0W2T93.GBP","IE00BQXX3F31.USD","BK4588","NDAQ","LU2210149790.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671982242","title":"Avalo Therapeutics Announces Inducement Grants to New Employees Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671982242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671982242?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:01","pubTimestamp":1790712060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUAVSBW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100952","title":"Avalo Therapeutics to Present Phase 2 LOTUS Trial Results for Abdakibart in Hidradenitis Suppurativa at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100952?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161228,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics to present Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa at EADV 2026Avalo Therapeutics flagged new Phase 2 LOTUS trial results for abdakibart in moderate-t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDLc6yqKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","NDAQ","BK4112","LU2210149790.SGD","AVTX","LU2095319765.USD","BCDF","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00BN0W2W23.USD","BK4588","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4585","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4139","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973858","title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of 12,394 Common Shares for $202,436.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973858","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973858?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:10","pubTimestamp":1789762239,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of 12,394 common shares for $202,436.79Avalo Therapeutics CFO Christopher Ryan Sullivan sold 12,394 common shares at USD 16.33 on Sep. 16, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL75P6nF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of 12,394 Common Shares for $202,436.79","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571267","title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of 10,185 Common Shares Worth $179,485.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571267","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571267?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:10","pubTimestamp":1789157443,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of 10,185 common shares worth $179,485.72Avalo Therapeutics CFO Christopher Ryan Sullivan exercised stock options for 10,185 common shares at ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL3ntzxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of 10,185 Common Shares Worth $179,485.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359473","title":"Avalo Therapeutics Grants 78,000 Inducement Stock Options Priced at $19.34 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359473","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665359473?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:05","pubTimestamp":1788552344,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics grants 78,000 inducement stock options priced at $19.34 per shareAvalo Therapeutics granted nonstatutory stock options covering 78,000 shares to six newly hired employees.Options we","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL5BDxn9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","SG9999014005.SGD","BCDF","IE00BQXX3C00.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU2095319765.USD","NDAQ","IE00BQXX3F31.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","AVTX","IE00BKPKM429.USD","BK4139","BK4585","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386948","title":"Avalo Therapeutics CMO Mittie Doyle Sells 679 Common Shares for $13,580","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386948","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664386948?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:39","pubTimestamp":1788295161,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle sells 679 common shares for $13,580Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 679 common shares at USD 20 on Aug. 28, 2026.The sale followed the exe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL44FJPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Sells 679 Common Shares for $13,580","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478020","title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of Common Shares Worth $1.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478020","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478020?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:11","pubTimestamp":1787170261,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of common shares worth $1.44 millionAvalo Therapeutics CFO Christopher Ryan Sullivan exercised stock options on Aug. 17-18 at USD 9.88.He sold","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLbGHJFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of Common Shares Worth $1.44 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490852","title":"Is Avalo Therapeutics (AVTX) Cheap As Wider Q2 Losses Meet A Lower P B?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490852?lang=en_us&edition=fundamental","pubTime":"2026-08-19 05:30","pubTimestamp":1787088626,"startTime":"0","endTime":"0","summary":"Q2 earnings highlight a wider net loss but improved per share figures\nAvalo Therapeutics (AVTX) reported second quarter and first half 2026 results, with higher net losses than a year earlier. Loss per share figures improved, which gives investors a mixed picture to assess.\nSee our latest analysis for Avalo Therapeutics.\nAvalo Therapeutics shares trade at US$19.71 after a recent 20.99% 90 day share price return and a 121.59% 1 year total shareholder return, although the 5 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/is-avalo-therapeutics-avtx-cheap-as-wider-q2-losses-meet-a-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/is-avalo-therapeutics-avtx-cheap-as-wider-q2-losses-meet-a-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AVTX","BK4139","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659090083","title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 679 Common Shares Worth $13,580","url":"https://stock-news.laohu8.com/highlight/detail?id=2659090083","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659090083?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:11","pubTimestamp":1786565465,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle disposes of 679 common shares worth $13,580Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 679 shares on Aug. 10 at USD 20.Sale followed an option exerci","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL6lxWWc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 679 Common Shares Worth $13,580","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657580536","title":"Avalo Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657580536","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657580536?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:05","pubTimestamp":1786028751,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAvalo Therapeutics IncAVTX.OQreported a quarterly adjusted loss of 83 cents per share for the quarter ended June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4432HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657063925","title":"CG Oncology Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657063925","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657063925?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:22","pubTimestamp":1786018956,"startTime":"0","endTime":"0","summary":"CG Oncology Q2 net loss widens on higher R&D costsOverviewUS biopharmaceutical firm's Q2 rev rose to $1.2 mln, reflecting early commercialization activityNet loss widened to $79.1 mln, driven by highe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4535","BK4139","CMPX","CHRS","SBIO","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763962","title":"Avalo Q2 2026 Earnings: $472.2 Million Supports 2027 Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763962","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763962?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:56","pubTimestamp":1786017369,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics reported a Q2 2026 net loss of $36.4 million, widening from $20.8 million, while diluted loss per share narrowed to $0.83 from $1.92 because weighted average shares increased sharply. R&D expense rose to $23.4 million, including a $10.0 million abdakibart milestone, and cash, equivalents and investments totaled $472.2 million at June 30. Management expects that balance to fund operations into 2029 as Avalo targets an abdakibart Phase 3 start and an AVTX-010 IND submission in the first half of 2027.","market":"fut","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock9.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock9.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262083419-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":-0.2418},{"period":"3month","weight":-0.3097},{"period":"6month","weight":-0.1193},{"period":"1year","weight":-0.2966},{"period":"ytd","weight":-0.3249}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0829},{"period":"1year","weight":0.1516},{"period":"ytd","weight":0.1337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.010519},{"month":3,"riseRate":0.272727,"avgChangeRate":0.280205},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.088879},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.046144},{"month":6,"riseRate":0.727273,"avgChangeRate":0.024954},{"month":7,"riseRate":0.454545,"avgChangeRate":0.02164},{"month":8,"riseRate":0.636364,"avgChangeRate":-0.026031},{"month":9,"riseRate":0.545455,"avgChangeRate":0.023005},{"month":10,"riseRate":0.545455,"avgChangeRate":0.128485},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction